Get started
Author

Thomas Yau

Observed names: Yau Thomas, Yau, Thomas
ORCID: 0000-0002-7114-0305
Observed ORCID: 0000-0002-7114-0305
OpenAlex ID: A5025533837
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
2024 · B. Sangro, S.L. Chan, et al. · Annals of Oncology · 362
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
2025 · Hani M. Babiker, Vincent Picozzi, et al. · Journal of Clinical Oncology · 48
PDF
Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants
2022 · Ye-fan Hu, Jing-chu Hu, et al. · Frontiers in Immunology · 14
Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.
2026 · Anthony Paul Conley, Seth M. Pollack, et al. · Journal of Clinical Oncology · 1
Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
2019 · Gin Wai Kwok, Vikki Tang, et al. · Journal of Clinical Oncology · 1
Fulminant tumour lysis syndrome after nivolumab and ipilimumab treatment for hepatocellular carcinoma
2025 · Gin Wai Kwok, Tiffany Hoi Wing Fung, et al. · Journal of Hepatology
Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
2023 · Marie-Luise Berres, Stephan L. Chan, et al. · Zeitschrift für Gastroenterologie
Comparison of Cetuximab and Bevacizumab as First-Line Treatment in KRAS Wild Type Advanced Colorectal Cancer Patients: A Retrospective Analysis
2014 · Zhang Qian, Yau Thomas, et al. · Annals of Oncology
Title Page / Table of Contents
2007 · Yasunori Minami, Hobyung Chung, et al. · Oncology
PDF
Works count: 10
Citation count: 425
H-index: 3
I10-index: 3
Year
Topic
Type